Compare HYI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HYI | TTRX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.2M | 116.0M |
| IPO Year | N/A | N/A |
| Metric | HYI | TTRX |
|---|---|---|
| Price | $10.78 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 68.2K | 20.8K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | ★ 9.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.44 | $2.57 |
| 52 Week High | $12.12 | $5.98 |
| Indicator | HYI | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 51.33 |
| Support Level | $10.44 | $2.98 |
| Resistance Level | $11.21 | $3.73 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 64.15 | 77.40 |
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.